FDA Awards Priority Voucher for Copper Drug Treating Kids' Disease
Published Date: 2/27/2026
Notice
Summary
The FDA just gave Sentynl Therapeutics a special priority review voucher for their new rare pediatric disease drug, ZYCUBO, which treats Menkes disease in kids. This voucher speeds up future FDA reviews, helping get important medicines to patients faster. The approval happened on January 12, 2026, and this voucher could also be sold or used to speed up other drug reviews, potentially saving time and money.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
ZYCUBO Approved for Menkes Disease
If you have a child with Menkes disease, the FDA approved ZYCUBO (copper histidinate) for treatment on January 12, 2026. This approval means pediatric patients with Menkes disease have an FDA‑approved treatment option.
Priority Review Voucher Can Speed Reviews
The FDA issued a Rare Pediatric Disease Priority Review Voucher tied to ZYCUBO; the voucher can be used or sold to speed the FDA review of another drug. If you or someone you care for needs a rare‑disease medicine, using or selling this voucher can help get other important drugs to patients faster and may save time and money.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in